The system of hepatocyte growth factor (HGF) and its receptor c-Met plays a critical role in tumor invasive growth and metastasis. The mortality rate of colorectal cancer (CRC), one of the most commonly diagnosed malignancies, is increased by it gradual development into metastasis, most frequently in the liver. Overexpression of c-Met, the protein tyrosine kinase receptor for the HCF/scatter factor, has been implicated in the progression and metastasis of human colorectal carcinoma. In this study, we aimed to investigate the role [1-4] CRC incidence and mortality rates are rapidly increasing over time, especially in low-income and middleincome countries, and the global burden of CRC is expected to surge by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. [5] [6] [7] [8] [9] CRC fatality is commonly caused by metastasis. Liver metastasis has been shown as one of the leading causes of death in patients with CRC. Previous studies have shown that about 25% of patients with CRC are clinically diagnosed with liver metastasis at the initial diagnosis, and approximately 50% of patients with CRC develop symptoms of liver metastasis during the course of their disease. Around 30% to 50% of patients with CRC display recurrent liver metastasis after radical resection and more than 50% succumb to the disease. [10] [11] [12] [13] [14] However, the current therapies for patients with CRC live metastasis, including surgery, radiotherapy, and chemotherapy treatment in the CRC metastasis, remain unsatisfactory due to rapid CRC metastasis deterioration and drug resistance. [10, 11] Hepatocyte growth factor (HGF) and its receptor, mesenchymalepithelial transition (c-Met), play an important role in several biological processes. [15] [16] [17] [18] [19] [20] [21] Under normal physiological conditions, the interaction
| INTRODUCTION
Colorectal cancer (CRC) is recognized as the third leading cause of cancer-related deaths worldwide. [1] [2] [3] [4] CRC incidence and mortality rates are rapidly increasing over time, especially in low-income and middleincome countries, and the global burden of CRC is expected to surge by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030. [5] [6] [7] [8] [9] CRC fatality is commonly caused by metastasis. Liver metastasis has been shown as one of the leading causes of death in patients with CRC. Previous studies have shown that about 25% of patients with CRC are clinically diagnosed with liver metastasis at the initial diagnosis, and approximately 50% of patients with CRC develop symptoms of liver metastasis during the course of their disease. Around 30% to 50% of patients with CRC display recurrent liver metastasis after radical resection and more than 50% succumb to the disease. [10] [11] [12] [13] [14] However, the current therapies for patients with CRC live metastasis, including surgery, radiotherapy, and chemotherapy treatment in the CRC metastasis, remain unsatisfactory due to rapid CRC metastasis deterioration and drug resistance. [10, 11] of HGF/c-Met strongly mediates cellular organization and cell division, such as epithelial cell proliferation and migration, angiogenesis, and wound healing. [18, 20] Whereas, the HGF/c-Met pathway is also involved in different types of malignant tumors and plays critical roles in tumor proliferation, invasion, and metastasis. [22] [23] [24] [25] Despite the increasing knowledge of the pathway bases of HGF/c-Met progression, the exact relationship between HGF/c-Met signaling and CRC and CRC liver metastasis remains a largely controversial topic. Therefore, in this study, we first determine whether the c-Met expression is correlated with CRC liver metastasis and then determine whether regulating HGF/c-MET signaling would be a new promising intervention to attenuate/ inhibit the progression of CRC metastasis.
| MATERIALS AND METHODS

| Patients groups
With institutional review and ethical approval of the Institutional 
| Western blot
RIPA buffer supplemented with protease and phosphatase inhibitors (Cat: 78441B; Thermo-Fisher, MA) was used for collecting about 10 mg protein estimated by the bicinchoninic acid method from the tissue that was frozen in liquid nitrogen. and fibroblast growth factor-basic was added to the samples. For passaging organoids, cultures should grow enough to 7 to 10 days.
The media was then removed from the well and add ice-cold PBS to melt the matrigel. Cultures were then centrifuged and dissociated by pipetting from disrupting organoids into small pieces and signal cells.
After removing the supernatant, the left crypt pellets were then resuspended in PBS and counted under a light microscope.
Approximately 50 crypt-like pellets were resuspended in Matrigel and followed by plating, as above. The passage number of cultures between 8 and 16 was used for further analysis. 
| Transwell assay
The cells treated with HGF were harvested as a single cell suspension at a density of 2 × 10 5 cells/mL in the presence of low-serum culture medium. Hundred microliters of this suspension was inoculated in the upper chamber of the transwell and 30% FBS was added into the lower chamber, and the assembly was incubated at 37°C, 5% CO 2 for 6 hours. The nontransferred cells were removed by a cotton swab.
The cells in the lower chamber were fixed and stained using crystal
violet. An average of five enumerations was utilized for the evaluation of cell invasion. The cells were collected for further qPCR detection. 
| c-Met RNA interference lentivirus design, packaging, and transduction
| Flow cytometry
| Statistical analysis
The statistical analyses were performed using the SPSS16.0 software. The data were presented as means + SD. A comparison between the two groups was carried out using the independent t test and between multiple groups using the single factor analysis of variance. A P value less than 0.05 was considered statistically significant for all analyses.
3 | RESULTS
| Expression of c-Met in primary CRC and liver metastasis
We assess the c-Met expression in CRC and the corresponding colon 3 It is well known that the lymph node metastasis incidence and its depth of tumor invasion are prognostic factors in malignant metastasis, including CRC metastasis. [18, 28, 29] Recently, HGF/c-Met signaling in various malignant tumors has been reported to be effective biologic markers for monitoring malignant potential. [30] [31] [32] In the current study, we have revealed the importance of c-Met expression in the prognosis and treatment of CRC metastasis. We demonstrated that c-Met expression was correlated with lymph node metastasis and the depth of tumor invasion. Although no clear relationship between serum HGF levels and clinical symptoms has been identified, [33] [34] [35] tumor budding in CRC, [15, 18, 21] to the best of our knowledge, this is A growing body of evidence-based research shows that c-Met tyrosine kinase inhibitors can block c-Met signaling and reverse tumor growth in different cancers. [15, [36] [37] [38] Recent studies have shown that MET signaling in lung cancer and gastric cancer is sensitive to inhibition using a specific tyrosine kinase inhibitor. [39] These findings suggested that overexpressed c-Met may act as an important biomarker for CRC targeted therapy. We therefore test 
